ACRV · NASDAQ · Biotechnology

Acrivon Therapeutics (ACRV)

Develops cancer therapies and companion diagnostics around drug-specific proteomic patient selection.

$2.15
Pre-market−0.00 (−0.23%)
At close$2.16(+4.11%)

Something off on this page? Send us feedback.

Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$0.45
Revenue estimate
$504.3K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.60−$0.51−$0.55−$0.47−$0.49−$0.49−$0.43Pending
Estimate−$0.69−$0.57−$0.57−$0.57−$0.49−$0.49−$0.50−$0.45
Surprise+13.0%+10.5%+3.5%+17.5%0.0%0.0%+14.4%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate$166.3K$277.2K$386.3K$504.3K
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.45
Aug 2026−$0.50−$0.43+14.4%
May 2026−$0.49−$0.490.0%
Mar 2026−$0.49−$0.490.0%
Nov 2025−$0.57−$0.47+17.5%

The latest year is open to everyone — the 16 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Dec 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 12, 2026−$0.45$504.3K
Aug 12, 2026−$0.50−$0.43+14.4%$386.3K+7.6%
May 13, 2026−$0.49−$0.490.0%$277.2K0.0%
Mar 19, 2026−$0.49−$0.490.0%$166.3K−2.4%
Nov 13, 2025−$0.57−$0.47+17.5%+8.2%

The latest year is open to everyone — the 16 quarters behind it read with an account.

Sign in
Aug 13, 2025
May 14, 2025
Mar 27, 2025
Nov 13, 2024
Aug 13, 2024
May 14, 2024
Mar 28, 2024
Nov 9, 2023
Aug 11, 2023
May 9, 2023
Mar 28, 2023
Nov 14, 2022
Aug 14, 2022
May 15, 2022
Feb 14, 2022
Dec 31, 2021